Introduction
Melasma is a common skin condition that can be difficult to treat. A commonly used treatment is Hydroquinone at 4%, but it may have side effects.
Study Objective
This study aimed to compare the effectiveness of an anti-hyperpigmentation serum (Serum B3) containing niacinamide, tranexamic acid, vitamin C, and hydroxy acids against Hydroquinone.
Study Design
In this study, 60 women aged 20 to 50 with facial melasma were divided into two groups:
- Group 1: Used Serum B3 for 5 months.
- Group 2: Used Hydroquinone for 3 months, then Serum B3 for 2 months.
We measured changes in melasma severity, skin hydration, and overall quality of life.
Results
Both groups showed significant improvement in pigmentation after 3 months. However, Group 1 had better skin hydration and tolerance. Quality of life improved in both groups after 84 days. The reduction in melanin density was similar for both groups.
Conclusion
Using Serum B3 for 5 months or Hydroquinone for 3 months followed by Serum B3 for 2 months showed similar effectiveness. However, Serum B3 was better tolerated and more accepted by patients.
Opportunities for Clinics and Patients
Based on the trial data, clinics can:
- Focus on using Serum B3 for improved patient satisfaction.
- Set clear goals for treatment outcomes based on melasma severity and patient feedback.
- Implement AI tools to track treatment effectiveness and patient responses.
Next Steps
Clinics should consider starting with a pilot project using Serum B3, monitor results, and expand based on findings.
Contact Us
For more information on AI solutions in medical management, reach out:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
